



KOLINPHARMA®  
LEADER TO HEALTH

**KOLINPHARMA: IN 2017 RANKED 5<sup>TH</sup> IN ITALY FOR REVENUES GROWTH AMONG THE  
OVER 2,000 COMPANIES OF THE NUTRACEUTICAL SECTOR  
AWARDED THE TENDER "INNODRIVER" TO FINANCE THE SCIENTIFIC RESEARCH**

Milan, July 11<sup>th</sup> 2018

*KOLINPHARMA®, Innovative SME operating in the nutraceutical sector, communicates that it reached the 5<sup>th</sup> place in Italy, according to New Line data, Federsalus' partner, for the revenues growth achieved in 2017, with +64,5%. Specifically, with a turnover of EUR 4.1 million, the Company is at the 116<sup>th</sup> place among the over 2,000 companies that represent the nutraceutical market in Italy, improving its 198<sup>th</sup> ranking of the previous year.*

*Emanuele Lusenti, KOLINPHARMA's CEO, said: "we are satisfied about our result that gives us the chance to be in the first places for our growth in Italy. This is the sign that the scientific dissemination and the innovation, which is our core business and that is the KOLINPHARMA's value proposition from the beginning, are producing tangible and desired results, pushing us to work in this direction."*

*Moreover, the Company won the tender "Innodriver", sponsored by Lombardy Region, of over EUR 40K, with the purpose to finance its scientific researches; in particular, on a popular disease in Italy and in the world, with the objective to reach a patented formulation that can be proposed to doctors and patients with the highest quality and innovation.*

*This press release is available online on our corporate website [www.kolinpharma.com](http://www.kolinpharma.com), in the section Investor Relations > Financial Press Releases.*

\*\*\*

*KOLINPHARMA® S.p.A., founded in 2013, is an Innovative SME operating in nutraceutical sector and specialised in the research and development, realised internally and in collaboration with the major Italian universities. The Company's products are made of innovative and natural raw materials and have the purpose of supporting the pharmacological treatments mainly for the diseases in the orthopaedic-physiatric and gynaecological fields. KOLINPHARMA distributes the products with its brand in the whole Italian territory through a skilled sales network of 66 medical-scientific representatives (MSRs), specialised sole agents graduated in scientific disciplines. The MSRs promote KOLINPHARMA's nutraceutical products directly to doctors, pointing at the specialists' awareness. The Company's direct clients are wholesalers, that distribute to pharmacies and para-pharmacies throughout Italy. KOLINPHARMA owns 4 patents in Italy and 9 certifications, of which 2 on the company and 7 on its products.*

**Contacts**

*IR TOP Consulting S.r.l  
Capital Markets & Investor Relations  
Floriana Vitale, Domenico Gentile  
[f.vitale@irtop.com](mailto:f.vitale@irtop.com) , [d.gentile@irtop.com](mailto:d.gentile@irtop.com)  
Via C. Cantù, 1 - 20123 Milan  
Tel.: +39 02 4547 3883/4*

*EnVent Capital Markets Ltd.  
Nominated Adviser (NOMAD)  
Francesca Martino  
[fmartino@enventcapitalmarkets.co.uk](mailto:fmartino@enventcapitalmarkets.co.uk)  
42 Berkeley Square - London W1J 5AW Italian  
Branch, via Barberini n. 95 - 00187 Rome  
Tel.: +39 06 896841 Fax: +39 06 89684155*

KOLINPHARMA S.p.A.  
SEDE OPERATIVA  
Corso Europa, 5  
20020 Lainate (MI)  
Tel. +39 02 94324300  
Fax +39 02 93571446

SEDE LEGALE  
Via Larga, 8  
20122 Milano

[info@kolinpharma.com](mailto:info@kolinpharma.com)  
C.F. e P. IVA 08331990963  
Cap. soc. € 1.639.571 i.v.  
R.E.A. MI-2018304

[www.kolinpharma.com](http://www.kolinpharma.com)

